Payment overview · 2025
General Payments
$1,536.90
67 reported records · 13 companies
Healthcare provider profile · identity verified
Noel Rubio, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CHICAGO, IL · NPI 1922036797
Verified facts
What the public records show
CMS Open Payments records show Noel Rubio, M.D. received $1,536.90 in general payments during 2025 across 67 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $322.25 | 21.0% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $223.03 | 14.5% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $195.38 | 12.7% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $191.00 | 12.4% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $147.48 | 9.6% | 7 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $109.07 | 7.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $85.16 | 5.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $70.83 | 4.6% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.61 | 4.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $54.96 | 3.6% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $32.11 | 2.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.02 | 1.6% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $18.00 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,536.90 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $347.06 | 15 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $198.22 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $198.22 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $191.00 | 9 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $147.48 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $127.72 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $109.07 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $85.16 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $79.60 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $63.61 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $54.96 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $53.45 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $46.69 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.21 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $32.11 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $18.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 21 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 132 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 677 | 224 |
| Losartan Potassium | Losartan Potassium | 287 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 242 | 82 |
| Lisinopril | Lisinopril | 237 | 75 |
| Metformin Hcl | Metformin Hcl | 200 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 45 |
| Nifedipine Er | Nifedipine | 139 | 48 |
| Omeprazole | Omeprazole | 137 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 135 | 44 |
| Jardiance | Empagliflozin | 132 | 56 |
| Gabapentin | Gabapentin | 124 | 48 |
| Chlorthalidone | Chlorthalidone | 114 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 40 |
| Famotidine | Famotidine | 103 | 41 |
| Furosemide | Furosemide | 103 | 38 |
| Carvedilol | Carvedilol | 96 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 34 |
| Allopurinol | Allopurinol | 75 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 26 |
| Ibuprofen | Ibuprofen | 75 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 28 |
| Ozempic | Semaglutide | 73 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 63 | 28 |
| Enalapril Maleate | Enalapril Maleate | 62 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 29 |
| Tradjenta | Linagliptin | 60 | 23 |
| Novolog Flexpen | Insulin Aspart | 59 | 17 |
| Montelukast Sodium | Montelukast Sodium | 56 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 17 |
| Linzess | Linaclotide | 53 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 16 |
| Single Use Swab | Alcohol Antiseptic Pads | 53 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 22 |
| Spironolactone | Spironolactone | 49 | 19 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 48 | 30 |
| Simvastatin | Simvastatin | 47 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 23 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 45 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 18 |
| Tramadol Hcl | Tramadol Hcl | 42 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 14 |
| Eliquis | Apixaban | 38 | 18 |
| Ezetimibe | Ezetimibe | 35 | 13 |
| Celecoxib | Celecoxib | 34 | 13 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 33 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | 18 |
| Telmisartan | Telmisartan | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | 11 |
| Meclizine Hcl | Meclizine Hcl | 28 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | 13 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 28 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 28 | 17 |
| Azelastine Hcl | Azelastine Hcl | 27 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 25 | 11 |
| Pregabalin | Pregabalin | 25 | 11 |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Prednisone | Prednisone | 22 | 13 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | 12 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Humira(Cf) Pen | Adalimumab | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,536.90 · 67 records | Boehringer Ingelheim Pharmaceuticals, Inc. | Cologuard Collection Kit, Dexcom G6 Transmitter, Doc Band, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, Kerendia, Korlym, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, Wegovy, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error